We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 13% above its sector, the market expects faster growth.
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes a diverse array of dosage formats, such as tablets, capsules, dry powders, suspensions, and injectable solutions. The company's active pharmaceutical ingredients cater to a broad spectrum of therapeutic applications, encompassing macrolides, antibacterials, anticonvulsants, anti-hypertensives, anti-helminthics, antihistamines, anti-acne treatments, anti-infectives, urologicals, anti-thrombotics, antidiabetics, pain management, gastroenterology, and cardiovascular medications. Established in 1958, Kopran Limited maintains its corporate headquarters in Mumbai, India.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save KOPRAN.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
